Fagron: FDA Warning Letter Creates New Entry Opportunity

2025-01-08 10:30:00 ET

Summary

• Fagron, a leader in pharmaceutical compounding, has refocused its M&A strategy, regaining market trust despite recent FDA issues, presenting a potential entry point.
• The company generated strong cash flows with a 14.4% revenue increase and a substantial net income jump, indicating robust financial health.
• Fagron maintains a low debt ratio, enabling continued strategic acquisitions and facility expansions, enhancing its growth potential.
• Trading at 15-16 times this year's earnings, Fagron's forward P/E ratio of 12 is appealing, especially with expected EBITDA growth and future M&A impacts.

Introduction

Fagron ( ARSUF ) is a Belgian company and a leader in the pharmaceutical compounding sector. The company went almost belly-up in 2016 as the high leverage ratio and the disappointing contribution from acquisitions started to bite. Fortunately, the company has learned from its mistakes and has recently been focusing on M&A targets that are more appropriate for a company of its size. It was able to regain the trust of the market, and the recent share price decrease related to an FDA letter outlining some issues with a plant in Wichita could provide an attractive entry point....

Read the full article on Seeking Alpha

For further details see: